Celldex Therapeutics (CLDX) Total Liabilities (2010 - 2026)

Celldex Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $55.0 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 50.8% year-over-year to $55.0 million in Q1 2026; TTM through Mar 2026 was $55.0 million, a 50.8% increase from a year earlier, with the FY2025 full-year figure at $55.8 million, up 23.12% from the prior year.
• Total Liabilities declined to $55.0 million in Q1 2026 per CLDX's latest filing, from $55.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $55.8 million in Q4 2025 and bottomed at $21.8 million in Q2 2023.
• The 5-year median for Total Liabilities is $36.5 million (2023), against an average of $35.7 million.
• Across the five-year window, Total Liabilities soared 70.05% in 2022 and plunged 42.5% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $26.5 million in 2022, then jumped by 37.41% to $36.5 million in 2023, then increased by 24.36% to $45.3 million in 2024, then increased by 23.12% to $55.8 million in 2025, then fell by 1.42% to $55.0 million in 2026.
• Per Business Quant, the three latest CLDX Total Liabilities figures stand at $55.0 million (Q1 2026), $55.8 million (Q4 2025), and $50.1 million (Q3 2025).